Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly
US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licenses to three Indian drug makers – Cipla, Sun Pharmaceuticals, and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in a statement. The firm added that discussions were also taking place with other Indian players for the grant of voluntary licenses to manufacture Baricitinib, which has recently found favor among clinicians for the treatment of Covid-19.
Luca Visini, managing director of Eli Lilly, India subcontinent, said that the firm has responded to the current surge of the pandemic in the country by issuing licenses for Baricitinib to accelerate its local manufacturing and distribution. “More licenses to additional Indian generic manufacturers are expected to be announced soon,” Visini added.
No comments:
Post a Comment